5-[[pyridin-3-yl-[3-(trifluoromethyl)phenyl]methylidene]amino]oxypenta noic acid

• CAT Number: M010599
• CAS Number: 110140-89-1
• Molecular Formula: C18H17F3N2O3
• Purity: ≥95%
• Target: Prostaglandin Receptor
• Storage: -20°C

Ridogrel is a dual action drug useful for the prevention of systemic thrombo-embolism and as an adjunctive agent to thrombolytic therapy in acute myocardial infarction. However, there currently are no clinical indications for preferential use of ridogrel over aspirin.

Reference

1: Tytgat GN, Van Nueten L, Van De Velde I, Joslyn A, Hanauer SB. Efficacy and safety of oral ridogrel in the treatment of ulcerative colitis: two multicentre, randomized, double-blind studies. Aliment Pharmacol Ther. 2002 Jan;16(1):87-99. PubMed PMID: 11856082. 2: Carty E, Rampton DS, Schneider H, Rutgeerts P, Wright JP. Lack of efficacy of ridogrel, a thromboxane synthase inhibitor, in a placebo-controlled, double-blind, multi-centre clinical trial in active Crohn/’s disease. Aliment Pharmacol Ther. 2001 Sep;15(9):1323-9. PubMed PMID: 11552902. 3: Naran NH, Chetty N. The in vitro effect of ridogrel on platelet function in normocholesterolaemic and familial hypercholesterolaemic type IIa subjects. Thromb Res. 1997 Dec 1;88(5):399-407. PubMed PMID: 9556227. 4: van der Wieken LR, Simoons ML, Laarman GJ, Van den Brand M, Nijssen KM, Dellborg M, Hermens W, Vrolik W. Ridogrel as an adjunct to thrombolysis in acute myocardial infarction. Int J Cardiol. 1995 Nov 24;52(2):125-34. PubMed PMID: 8749872. 5: Keith JC Jr, Endo Y, Warwick K, Keith KE, Brugh S, Rowles TK. Ridogrel improves maternal/fetal homeostasis in an ovine model of pregnancy-induced hypertension. Prostaglandins. 1994 Mar;47(3):247-63. PubMed PMID: 8016393. 6: Randomized trial of ridogrel, a combined thromboxane A2 synthase inhibitor and thromboxane A2/prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction. The Ridogrel Versus Aspirin Patency Trial (RAPT). Circulation. 1994 Feb;89(2):588-95. PubMed PMID: 8313547. 7: Keith JC Jr, Goodrich JA, Endo Y, Taub D, Mehlman P, Ward G. Effects of ridogrel on the prostacyclin-thromboxane ratio in nulliparous third trimester-pregnant rhesus monkeys. Prostaglandins. 1993 Jun;45(6):547-55. PubMed PMID: 8337414. 8: Vanden Bossche H, Willemsens G, Bellens D, Janssen PA. Ridogrel: a selective inhibitor of the cytochrome P450-dependent thromboxane synthesis. Biochem Pharmacol. 1992 Feb 18;43(4):739-44. PubMed PMID: 1540227. 9: Di Perri T, Notari M, Assogna G. [Ridogrel, a new platelet antiaggregant molecule with a double mechanism of action. A pharmacological and clinical profile]. Recenti Prog Med. 1991 Oct;82(10):533-40. Italian. PubMed PMID: 1759039. 10: Janssens WJ, Cools FJ, Hoskens LA, Van Nueten JM. Effect of ridogrel on vascular contractions caused by vasoactive substances released during platelet activation. Thromb Haemost. 1990 Aug 13;64(1):91-6. PubMed PMID: 2148850. 11: Auwerda JJ, Zijlstra FJ, Tak CJ, van den Ingh HF, Wilson JH, Ouwendijk RJ. Ridogrel enemas in distal ulcerative colitis. Eur J Gastroenterol Hepatol. 2001 Apr;13(4):397-400. PubMed PMID: 11338069. 12: Carty E, Macey M, McCartney SA, Rampton DS. Ridogrel, a dual thromboxane synthase inhibitor and receptor antagonist: anti-inflammatory profile in inflammatory bowel disease. Aliment Pharmacol Ther. 2000 Jun;14(6):807-17. PubMed PMID: 10848666. 13: Ridogrel. R 68070. Drugs R D. 1999 Mar;1(3):270-2. PubMed PMID: 10566044. 14: Schneider TJ, Struijk PC, Wallenburg HC. Placental transfer of the thromboxane synthetase inhibitor ridogrel in the late-pregnant ewe. Eur J Obstet Gynecol Reprod Biol. 1999 Sep;86(1):83-7. PubMed PMID: 10471147. 15: Quest DW, Wilson TW. Effects of ridogrel, a thromboxane synthase inhibitor and receptor antagonist, on blood pressure in the spontaneously hypertensive rat. Jpn J Pharmacol. 1998 Dec;78(4):479-86. PubMed PMID: 9920205. 16: Heinisch G, Holzer W, Kunz F, Langer T, Lukavsky P, Pechlaner C, Weissenberger H. On the bioisosteric potential of diazines: diazine analogues of the combined thromboxane A2 receptor antagonist and synthetase inhibitor Ridogrel. J Med Chem. 1996 Sep 27;39(20):4058-64. PubMed PMID: 8831771. 17: Tranchesi B, Pileggi F, Vercammen E, Van de Werf F, Verstraete M. Ridogrel does not increase the speed and rate of coronary recanalization in patients with myocardial infarction treated with alteplase and heparin. Eur Heart J. 1994 May;15(5):660-4. PubMed PMID: 8056007. 18: Hoet B, Arnout J, Deckmyn H, Vermylen J. Synergistic antiplatelet effect of ridogrel, a combined thromboxane receptor antagonist and thromboxane synthase inhibitor, and UDCG-212, a cAMP-phosphodiesterase inhibitor. Thromb Haemost. 1993 Nov 15;70(5):822-5. PubMed PMID: 8128441. 19: De Cree J, Geukens H, Gutwirth P, De Clerck F, Vercammen E, Verhaegen H. The effect of a combined administration of ridogrel and ketanserin in patients with intermittent claudication. Int Angiol. 1993 Mar;12(1):59-68. PubMed PMID: 8376914. 20: Weber C, Beetens JR, Tegtmeier F, Van Rooy P, Vercammen E, Wouters L, De Clerck F. Ridogrel inhibits systemic and renal formation of thromboxane A2 and antagonizes platelet thromboxane A2/prostaglandin endoperoxide receptors upon chronic administration to man. Thromb Haemost. 1992 Aug 3;68(2):214-20. PubMed PMID: 1412169.